Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Overview of attention for article published in Trials, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#28 of 6,034)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 4 news outlets

twitter: 145 tweeters

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 22 Mendeley

Summary News Twitter Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Ivermectin for COVID-19: The 2022 Update

Article in American Journal of Therapeutics (November 2022)

Care for adults with COVID‐19: living guidelines from the National COVID‐19 Clinical Evidence Taskforce

Article in The Medical Journal of Australia (September 2022)

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Article in Clinical Infectious Diseases (September 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.